Over the past day, 16,474 new cases of coronavirus have been detected in Russia.
24,822 patients were discharged, 526 people died from complications that developed against the background of COVID-19, and concomitant diseases.
The total number of cases of coronavirus infection recorded in the country since the beginning of the pandemic has reached 3,901,204. 3,365,367 people have recovered, 74,684 died.
The largest number of COVID-19 cases was registered in St. Petersburg (1916), Moscow (1545) and the Moscow region (713).
The government of the Primorsky Territory reported that the situation with coronavirus in the region has stabilized, there is a trend towards a decrease in the incidence.
In the Murmansk region, a number of restrictions have been lifted.
In particular, they allowed the work of food courts, the organization of outdoor leisure activities, the occupancy rate in theaters and cinemas is increasing to 75%.
In the Stavropol Territory, mandatory self-isolation for those who come to the region has been canceled, and in the Voronezh Region, routine admission to hospitals is resumed.
In addition, according to the decision of the operational headquarters to combat the spread of COVID-19, international flights from the airports of Kemerovo and Petropavlovsk-Kamtchatsky are resumed.
The press service of Rospotrebnadzor reported that more than 102.8 million laboratory tests were carried out in the Russian Federation for the presence of coronavirus.
More than 626 thousand people remain under medical supervision.
In addition, the President of the Russian Academy of Sciences Alexander Sergeev said that in the near future the results of tests of a therapeutic monoclonal antibody molecule that neutralizes the SARS-CoV-2 coronavirus will be transferred to the Ministry of Health.
“Employees of the Institute of Bioorganic Chemistry of the Russian Academy of Sciences, together with their Chinese colleagues, proposed an original therapeutic neutralizing antibody.
It completely turns off the ability of the virus to penetrate the cell.
The test results will soon be submitted to the Ministry of Health for obtaining permission to conduct clinical trials on patients with COVID19 who have a number of concomitant diseases, including diabetes, ”Sergeev said.
The Institute of Bioorganic Chemistry, the Russian company Pharmsynthez and the international biopharmaceutical company HifiBio Therapeutics are engaged in joint development.
RIA News
© Evgeny Kozyrev
According to the World Health Organization, in the week from January 25 to January 31, there was a record number of deaths in the world - 96 364. The previous highest death rate was set in the week from January 18 to 24 (95 991).
At the same time, WHO stressed that the incidence of coronavirus infection in the world has been declining for the third week in a row.
As follows from the data of Johns Hopkins University, at the moment around the world from complications caused by COVID-19 and other concomitant diseases, more than 2.25 million people have died.
The largest number of deaths was registered in the United States (446 thousand), Brazil (226 thousand) and Mexico (159 thousand).
At the same time, the USA (26.4 million), India (10.7 million) and Brazil (9.2 million) are leading in the number of detected cases of coronavirus.
In the meantime, the Federal Commission for the Protection against Sanitary Risks of Mexico has registered the Russian vaccine against coronavirus infection Sputnik V.
This was reported by the press service of the Russian Direct Investment Fund.
It is noted that registration was carried out as part of an accelerated procedure without additional clinical studies.
Thus, Mexico became the 17th country in the world to approve a Russian drug, as well as the first state from North America.
“We welcome the decision of the Mexican regulatory authorities to register the Sputnik V vaccine and its inclusion in the national portfolio of drugs against coronavirus.
The partnership between Russia and Mexico will help save lives of many people and protect the population thanks to one of the best vaccines in the world, the high efficiency of which was confirmed the day before by the publication of data in the leading medical journal The Lancet, ”said RDIF CEO Kirill Dmitriev.
Previously, the use of the vaccine developed by the specialists of the NITsEM named after honorary academician N.F.
Gamalea has been approved in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia and Armenia.
On the eve of the journal The Lancet published the results of the third phase of clinical trials "Sputnik V", which demonstrated high efficiency, immunogenicity and safety.
The information provided by the specialists of the Gamaleya Center was confirmed by the results of an international expert assessment.
Later, the Greek health specialist Professor Ilias Mosialos stressed that he expected a similar result.
“We are awaiting news on the progress of the Russian vaccine dossier in the EU and look forward to news on the protection it provides against new variants of the virus.
At the same time, it is also very important that many other countries have concluded agreements on the purchase of the Russian vaccine and soon thousands of people will be vaccinated with it.
The pandemic will not end unless massive vaccinations are carried out around the world, ”he wrote on Facebook.